Contraindications
Severe organic heart disease (e.g. bradycardia, ischaemic heart disease, CHF), acute renal failure, urinary retention, phaeochromocytoma, thyrotoxicosis, persistent and excessive supine HTN.
|
Special Precautions
Patient w/ DM, history of visual problems (esp when taken w/ fludrocortisone). Hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor supine and sitting BP; hepatic and renal function.
|
Adverse Reactions
Supine and sitting HTN, bradycardia, paraesthesia, pilomotor reaction, chills, pruritus, rash; urinary urge, urinary retention, urinary frequency; headache, fullness in the head, vasodilation, flushing face, confusion, dry mouth, anxiety. Rarely, visual field defect, dizziness, skin hyperaesthesia, insomnia, somnolence, erythema multiforme, canker sore, dry skin; dysuria, impaired urination, asthenia, backache, pyrosis, GI distress, flatulence, leg cramps.
|
Drug Interactions
Enhanced pressor effects w/ α-adrenergic agonists (e.g. phenylephrine, ephedrine, dihydroergotamine, phenylpropanolamine, pseudoephedrine). Reduced effect w/ α-adrenergic blockers (e.g. prazosin, terazosin, doxazosin). May precipitate bradycardia, AV block, or arrhythmia w/ cardiac glycosides.
|
CIMS Class
|
ATC Classification
C01CA17 - midodrine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
|